0 Bedömningar
ID

13094

Beskrivning

Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00623610

Länk

https://clinicaltrials.gov/show/NCT00623610

Nyckelord

Versioner (1)
  1. 2016-01-15 2016-01-15 -
Uppladdad den

15 januari 2016

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

  • Senaste
  • Äldsta
  • Önskad
  • Senaste
    • Senaste
    • Äldsta
    • Önskad

    Inga kommentarer

    Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

    Eligibility Diabetes Mellitus, Type 1 NCT00623610

    Engelsk

    Eligibility Diabetes Mellitus, Type 1 NCT00623610

    1 Formulär  
    Inclusion Criteria
    Beskrivning

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    type 1 insulin-dependent diabetic patients in relatively good general condition
    Beskrivning

    type 1 diabetes, health status

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0011854
    UMLS CUI [2]
    C0018759
    non-smoker
    Beskrivning

    tobacco use

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0543414
    body weight < 80 kg
    Beskrivning

    weight

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0005910
    c-peptide < 0.03 nmol/l (<0.09 µg/l) 6 min. after glucagon iv (1mg) (glycemia > 180 mg/dl)
    Beskrivning

    c-peptide after glucagon

    Datatyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0202100
    UMLS CUI [1,2]
    C0332282
    UMLS CUI [1,3]
    C0017687
    ebv antibody positive
    Beskrivning

    ebv antibody positive

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0241883
    cooperative and reliable patient giving informed consent by signature; the patient should be informed in sufficient detail on the content and procedure of the protocol, indicating potential risks of intervention and of immunosuppressive therapy; the patient should also be informed that withdrawal of immunosuppressive therapy in patients with persistent plasma c-peptide positivity may result in subsequent loss of ß-cell graft function; the ß cell implant should be identified as a clinical trial.
    Beskrivning

    informed consent, compliance

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0021430
    UMLS CUI [2]
    C1321605
    Exclusion Criteria
    Beskrivning

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    history of thrombosis or pulmonary embolism
    Beskrivning

    thrombosis, pulmonary embolism

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0040053
    UMLS CUI [2]
    C0034065
    abnormal liver function
    Beskrivning

    liver dysfunction

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0086565
    hla antibodies
    Beskrivning

    hla antibodies

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0024284
    Tillbaka till toppen

    Similar models

    Eligibility Diabetes Mellitus, Type 1 NCT00623610

    1 Formulär
    Name
    Typ
    Description | Question | Decode (Coded Value)
    Datatyp
    Alias
    Item Group
    C1512693 (UMLS CUI)
    type 1 diabetes, health status
    Item
    type 1 insulin-dependent diabetic patients in relatively good general condition
    boolean
    C0011854 (UMLS CUI [1])
    C0018759 (UMLS CUI [2])
    tobacco use
    Item
    non-smoker
    boolean
    C0543414 (UMLS CUI [1])
    weight
    Item
    body weight < 80 kg
    boolean
    C0005910 (UMLS CUI [1])
    c-peptide after glucagon
    Item
    c-peptide < 0.03 nmol/l (<0.09 µg/l) 6 min. after glucagon iv (1mg) (glycemia > 180 mg/dl)
    boolean
    C0202100 (UMLS CUI [1,1])
    C0332282 (UMLS CUI [1,2])
    C0017687 (UMLS CUI [1,3])
    ebv antibody positive
    Item
    ebv antibody positive
    boolean
    C0241883 (UMLS CUI [1])
    informed consent, compliance
    Item
    cooperative and reliable patient giving informed consent by signature; the patient should be informed in sufficient detail on the content and procedure of the protocol, indicating potential risks of intervention and of immunosuppressive therapy; the patient should also be informed that withdrawal of immunosuppressive therapy in patients with persistent plasma c-peptide positivity may result in subsequent loss of ß-cell graft function; the ß cell implant should be identified as a clinical trial.
    boolean
    C0021430 (UMLS CUI [1])
    C1321605 (UMLS CUI [2])
    Item Group
    C0680251 (UMLS CUI)
    thrombosis, pulmonary embolism
    Item
    history of thrombosis or pulmonary embolism
    boolean
    C0040053 (UMLS CUI [1])
    C0034065 (UMLS CUI [2])
    liver dysfunction
    Item
    abnormal liver function
    boolean
    C0086565 (UMLS CUI [1])
    hla antibodies
    Item
    hla antibodies
    boolean
    C0024284 (UMLS CUI [1])
    Tillbaka till toppen 

    Hjälp

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial